Editors:
A concise overview of ground breaking novel incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors
Ideal for busy clinicians who encounter patients with type 2 diabetes on a daily basis and are interested in a clinically-applicable introduction to incretin-based therapies
Includes the most up-to-date clinical guidelines, recent clinical trials and expert discussions of established and emerging therapies for patients with type 2 diabetes
Includes supplementary material: sn.pub/extras
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
About this book
Keywords
- Diabetes
- Type 2 diabetes
- DPP-4 inhibitor
- GLP-1 analogue
- Incretin
- Dipeptidyl peptidase-4 inhibitor
- Gliptins
- Glucagon-like peptide-1 agonist
- Incretin mimetics
- Oral hypoglycemics
- Oral antidiabetics
- Sitagliptin
- Saxagliptin
- Vildagliptin
- Alogliptin
- Linagliptin
- Exenatide
- Liraglutide
- Lixisenatide
- Dulaglutide
Editors and Affiliations
-
Oxford Ctre for Diabe, Endocrngy & Metab, Oxford University, Oxford, United Kingdom
Stephen Gough
About the editor
Addendum
Since editing this book, Professor Gough has taken up the position of Senior Principal Clinical Scientist with Novo Nordisk. He continues as Visiting Professor of Diabetes at the University of Oxford and Honorary Consultant with the Oxford University Hospitals NHS Trust.
Bibliographic Information
Book Title: Handbook of Incretin-based Therapies in Type 2 Diabetes
Editors: Stephen Gough
DOI: https://doi.org/10.1007/978-3-319-08982-9
Publisher: Adis Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer International Publishing Switzerland 2016
Softcover ISBN: 978-3-319-08981-2Published: 17 June 2016
eBook ISBN: 978-3-319-08982-9Published: 07 June 2016
Edition Number: 1
Number of Pages: IX, 92
Number of Illustrations: 4 b/w illustrations, 16 illustrations in colour
Topics: Diabetes